Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Trastuzumab in HER2-mutant Breast Cancer
NCT01557764Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2012
- Primary completion
- Mar 2016
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
A Phase 2 trial of lapatinib, trastuzumab in breast cancer, sponsored by Washington University School of Medicine. Planned start Sep 2012; status: withdrawn.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01557764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557764.